Skip to content

Author

Bing Chen

We have 2 of 35 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

AI-driven dual-task prediction model for co-stratifying efficacy and toxicity in NSCLC immunotherapy

While effective against non-small cell lung cancer (NSCLC), PD-1 inhibitors can induce immune-related adverse events (irAEs), occurring in up to 15.2% of patients and potentially fatal. Currently, effective predictive biomarkers capable of simultaneously forecasting both irAEs and immune checkpoint inhibitor (ICI) resp...

Hanlin Ding, Yu-Ting Ren, Siqi Ding et al. · 0 citations
Open access Aug 2026

Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer

This study identified UBE2C+ proliferative tumor cells as a functionally relevant malignant subpopulation in SCLC and links this state to immune-stromal communication networks within the tumor microenvironment and provides a systems-level framework for investigating the cancer-immunity regulome in SCLC.

Hong-Ling Jia, Yongxuan An, Bing Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.